Companies in #Cardiometabolic Disease

City Therapeutics is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) medicines, founded by John Maraganore (former CEO of Alnylam Pharmaceuticals) and a team of RNAi pioneers. The company's lead platform is based on cleavage-inducing tiny guide RNAs (cityRNAs) designed to improve potency and durability over first-generation siRNA therapeutics, with three programs in the pipeline targeting cardiometabolic and rare diseases.

Korro Bio is a clinical-stage biopharmaceutical company developing genetic medicines based on RNA editing for rare and highly prevalent diseases. Its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform uses GalNAc-conjugated oligonucleotides to recruit endogenous adenosine deaminase acting on RNA for precise, transient single-base edits, an approach designed to avoid the permanent DNA cuts associated with gene editing. The company's lead programme, KRRO-121, is in the Phase 1/2 ANCHOR trial in healthy volunteers for hyperammonemia associated with urea cycle disorders and hepatic encephalopathy; KRRO-111 is in late preclinical development for alpha-1 antitrypsin deficiency, targeting both the lung and liver manifestations of the disease, with a regulatory submission and first-in-human entry guided for the first half of 2027. Korro also has discovery programmes in neurologic and pain indications and a collaboration with Novo Nordisk covering cardiometabolic disease. The company is headquartered in Cambridge, Massachusetts and trades on the Nasdaq Global Market under the ticker KRRO.

Novo Nordisk is a Danish multinational pharmaceutical company that discovers, develops, and markets therapies for diabetes, obesity, rare endocrine disorders, and other chronic diseases. The company is the world's largest insulin producer and a leading developer of GLP-1 receptor agonists for diabetes (Ozempic, Rybelsus) and obesity (Wegovy), with a deep pipeline in cardiometabolic and rare-disease therapeutics.

Clinical-stage cardiometabolic biotech developing next-generation oral and injectable peptide therapies for obesity and related metabolic conditions, led by an oral formulation of ecnoglutide and a portfolio of amylin-based candidates.